Print Page  |  Close Window

Investor Relations

Corporate Profile

Navidea Biopharmaceuticals is a commercial stage biotechnology company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing the precision-targeted Manocept™ platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

Today's Quote

NAVB (Common Stock)
ExchangeNYSE Amex (US Dollar)
Price$0.52
Change (%) Stock is Up 0.01 (1.96%)
Volume616,101
Data as of 04/26/17 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent Press Releases

More Press Releases >
DateTitle
04/25/17Navidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences
03/29/17Navidea Provides Corporate Update and Reports Full Year 2016 Results
03/03/17Navidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health
01/27/17Navidea to Hold Conference Call to Provide Investor Update on Status of Ongoing Corporate Events

Upcoming Events

Navidea Biopharmaceuticals Inc at Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Monday, June 12, 2017 4:45 p.m. ET
Description

Navidea has been invited to present its Tc99m-tilmanocept receptor-specific diagnosis data for aortic plaques (Nav/MGH), and for rheumatoid arthritis (Nav3-21/23), at the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a meeting of leading molecular imaging and nuclear medicine experts representing the world’s top medical and academic institutions and centers.

   

Time:

June 12, 4:45 - 6:15 PM – Rm 708/710 (Cardio)
June 12, 4:45 - 6:15 PM – Rm 603 (Rheumatoid)
LocationColorado Convention Center
700 14th Street
Denver, CO 80202
Add to Calendar Add Navidea Biopharmaceuticals Inc at Society of Nuclear Medicine and Molecular Imaging Annual Meeting to Calendar  Help
remind me days before the event

Navidea Biopharmaceuticals Inc at 2017 BIO International Convention
Monday, June 19, 2017
Description

Navidea has been selected by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a component of the National Institute of Health (NIH) to present its Rheumatoid Arthritis (RA) program to investors at the 2017 BIO International Convention (BIO 2017). Navidea was selected from more than 1,000 recipients of NIH/NIAMS SBIR grants to present clinical results and their commercial strategy in regards to the development of tilmanocept (Tc99m-Tilmanocept), for the diagnostic imaging of RA.

   

Event:

2017 Bio International Convention

Date:

June 19-22, 2017

Time:

TBD
LocationSan Diego Convention Center
111 W. Harbor Drive
San Diego, CA 92101
Add to Calendar Add Navidea Biopharmaceuticals Inc at 2017 BIO International Convention to Calendar  Help
remind me days before the event

Enter your e-mail address 

News and Information

More News and Information >
DateTitle
04/24/17Navidea/Macrophage Therapeutics selected for oral presentations and The Society of Nuclear medicine and Molecular Imaging (SNMMI) Annual Meeting in Denver.
04/24/17Navidea selected by NIH/NIAMS to present Rheumatoid Arthritis program to investors at Bio International in San Diego June 19-22, 2017
04/24/17Navidea/Macrophage Therapeutics Completes Sentinel Node Biopsy Evaluation in Prospective Study of Tc99m Tilmanocept in Cervical Cancer.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.